Ipilimumab-induced thrombotic thrombocytopenic purpura (TTP)

BACKGROUND: CTLA-4 (Cytotoxic T-lymphocyte-associated protein 4) was the first immune checkpoint receptor clinically targeted for use in cancer treatment. It is expressed exclusively on T-cells where its primary role is to regulate the amplitude of the early stages of T-cell activation.1 Ipilimumab,...

Descripción completa

Detalles Bibliográficos
Autores principales: King, Jeanelle, de la Cruz, Javier, Lutzky, Jose
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5360069/
https://www.ncbi.nlm.nih.gov/pubmed/28344807
http://dx.doi.org/10.1186/s40425-017-0224-7

Ejemplares similares

Ejemplares similares